Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Capecitabine in Advanced Renal Cell Cancer
NCT00058318Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Dec 2004
- Primary completion
- May 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Phase 2, open-label trial of gemcitabine and capecitabine in renal cell carcinoma (RCC), sponsored by SWOG Cancer Research Network. Primary endpoint: Objective Response Rate. Started Dec 2004; status: completed.
02
Drugs
gemcitabinecapecitabine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00058318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058318.